BridgeMD
New treatment option for Invasive Breast Cancer
Official title Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy
ClinicalTrials.gov ID: NCT06926543
What this study is testing
What is Chemoradiation?
Chemoradiation is an investigational medicine, being studied as a potential treatment for invasive breast cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical research aims to determine if concurrent chemotherapy and radiation therapy is more effective than sequential chemotherapy and radiation therapy for patients with stage IIB-III breast cancer. It seeks to answer the following key questions: 1.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Pathologically confirmed invasive breast cancer
- Stage IIB-III invasive breast cancer (AJCC 8th edition)
- Patients planned for adjuvant chemotherapy and adjuvant radiotherapy
- Patients fit to receive adjuvant chemotherapy and radiotherapy
- Age \> 18 years
You likely can't join if
- Hypersensitivity to taxanes
- Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting)
- Unable or unwilling for regular follow up
- Bilateral tumour needed RT to both sides
- Patients planned for RT to oligometastatic sites
- Unfavourable anatomical factors potentially leading to higher radiotherapy dose to heart and/or lungs (Exceeding the protocol specific mandatory dose...
See the full eligibility criteria
- Pathologically confirmed invasive breast cancer
- Stage IIB-III invasive breast cancer (AJCC 8th edition)
- Patients planned for adjuvant chemotherapy and adjuvant radiotherapy
- Patients fit to receive adjuvant chemotherapy and radiotherapy
- Age \> 18 years
- Hypersensitivity to taxanes
- Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting)
- Unable or unwilling for regular follow up
- Bilateral tumour needed RT to both sides
- Patients planned for RT to oligometastatic sites
- Unfavourable anatomical factors potentially leading to higher radiotherapy dose to heart and/or lungs (Exceeding the protocol specific mandatory dose constraints).
- Pregnant patient
The study team makes the final eligibility decision.
Where it's taking place
- Vishkhapatnam, Andhra Pradesh, India
- Mumbai, Maharasthra, India
- New Chandigarh, Punjab, India
- Sangrur, Punjab, India
- Varanasi, Uttar Pradesh, India
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Vishkhapatnam, Andhra Pradesh, India; Mumbai, Maharasthra, India; New Chandigarh, Punjab, India; Sangrur, Punjab, India; Varanasi, Uttar Pradesh, India. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.